Catalysts About BioVersys BioVersys develops antibiotics and anti infective therapies targeting high mortality, drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About BioVersys BioVersys is a biopharmaceutical company focused on developing antibiotics for severe drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About BioVersys BioVersys is a clinical stage biopharmaceutical company focused on antibiotics targeting severe drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?Read more
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
